Val8-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats

Journal of Neuroscience Research

Volumn 91, Issue 4, 2013, Pages 568-577

  Wang, Xiao Hui ^a   Yang, Wei ^a   Hölscher, Christian ^b   Wang, Zhao Jun ^a   Cai, Hong Yan ^a   Li, Qing Shan ^a   Qi, Jin Shun ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Amyloid ; Intracellular calcium concentration; Miniature postsynaptic currents; Peptide; Val8 GLP 1(7 36)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; CALCIUM; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; VALINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CALCIUM HOMEOSTASIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; MOLECULAR IMAGING; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SYNAPTIC TRANSMISSION;

AMYLOID BETA-PEPTIDES; ANIMALS; CA1 REGION, HIPPOCAMPAL; CALCIUM; CELLS, CULTURED; CEREBRAL CORTEX; EXCITATORY POSTSYNAPTIC POTENTIALS; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; INHIBITORY POSTSYNAPTIC POTENTIALS; MINIATURE POSTSYNAPTIC POTENTIALS; NEURONS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84873718532     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23181     Document Type: Article

References (43)

1. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. 1991. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1: 103-116.
2. Auger C, Marty A. 2000. Quantal currents at single-site central synapses. J Physiol 526: 3-11.
3. Deacon CF, Johnsen AH, Holst JJ. 1995. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957.
4. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. 2003. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9: 1173-1179.
5. Fraser SP, Suh YH, Djamgoz MB. 1997. Ionic effects of the Alzheimer's disease beta-amyloid precursor protein and its metabolic fragments. Trends Neurosci 20: 67-72.
6. Fu H, Li W, Lao Y, Luo J, Lee NT, Kan KK, Tsang HW, Tsim KW, Pang Y, Li Z, Chang DC, Li M, Han Y. 2006. Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. J Neurochem 98: 1400-1410.
7. 8GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging 33: 265-276.
8. Goodman Y, Mattson MP. 1994. Secreted forms of β-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp Neurol 128: 1-12.
9. 8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 318: 914-921.
10. Green KN, Smith IF, Laferla FM. 2007. Role of calcium in the pathogenesis of Alzheimer's disease and transgenic models. Subcell Biochem 45: 507-521.
11. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
12. Hamilton A, Holscher C. 2009. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 20: 1161-1166.
13. Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. 2011. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 89: 481-489.
14. Han WN, Holscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS. 2012. Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging (in press).
15. Hardy J. 1997. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20: 154-159.
16. Holscher C, Li L. 2010. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol Aging 31: 1495-1502.
17. 2+-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270: 17749-17757.
18. 2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 274: 14147-14156.
19. Hunter K, Holscher C. 2012. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 13: 33.
20. Kelly BL, Ferreira A. 2006. β-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 281: 28079-28089.
21. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. 2004. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24: 10191-10200.
22. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. 2007. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796-807.
23. LaFerla FM. 2002. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3: 862-872.
24. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH. 2010. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19: 1205-1219.
25. Malgaroli A, Tsien RW. 1992. Glutamate-induced long-term potentiation of the frequency of miniature synaptic currents in cultured hippocampal neurons. Nature 357: 134-139.
26. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82: 4245-4249.
27. McClean PL, Parthsarathy V, Faivre E, Holscher C. 2011. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31: 6587-6594.
28. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866.
29. Mora F, Exposito I, Sanz B, Blazquez E. 1992. Selective release of glutamine and glutamic acid produced by perfusion of GLP-1 (7-36) amide in the basal ganglia of the conscious rat. Brain Res Bull 29: 359-361.
30. 1-42 globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci 28: 788-797.
31. Oertner TG, Sabatini BL, Nimchinsky EA, Svoboda K. 2002. Facilitation at single synapses probed with optical quantal analysis. Nat Neurosci 5: 657-664.
32. Oka JI, Goto N, Kameyama T. 1999. Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus. Neuroreport 10: 1643-1646.
33. Orskov C, Poulsen SS, Moller M, Holst JJ. 1996. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832-835.
34. Perez-Cruz C, Nolte MW, van Gaalen MM, Rustay NR, Termont A, Tanghe A, Kirchhoff F, Ebert U. 2011. Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J Neurosci 31: 3926-3934.
35. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. 2002. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881-888.
36. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. 2003. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72: 603-612.
37. Qi JS, Qiao JT. 2001. Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons. Neuroscience 105: 845-852.
38. 2+ homeostasis. Brain Res 1143: 11-21.
39. Segal M, Andersen P. 2000. Dendritic spines shaped by synaptic activity. Curr Opin Neurobiol 10: 582-586.
40. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. 1991. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580.
41. Thal DR, Rub U, Orantes M, Braak H. 2002. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800.
42. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. 2009. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510.
43. 8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170: 1239-1248.